Literature DB >> 620477

Methadone maintenance: plasma levels and therapeutic outcome.

J Holmstrand, E Anggård, L M Gunne.   

Abstract

Twenty-one opiate-dependent subjects were inducted into methadone maintenance treatment (MMT) in a closed metabolic ward. A daily dose of 30 mg of d, 1-methadone was given for 10 to 24 days followed by 60 mg/day for another 10 to 24 days. Analysis of plasma levels at 4-day intervals showed accumulation to a peak followed by a decrease to a lower level, indicative development of dispositional tolerance. The outcome of treatment was assessed after 21 to 43 mo (median, 33 mo). The best record of rehabilitation was obtained in subjects discharged with steady-state plasma concentrations above 200 ng/ml. Lower levels of plasma methadone were associated with higher frequency of urines containing illicit drugs and poorer psychosocial rehabilitation. This study indicates that a pharmacokinetically optimized dosage regimen would be useful in increasing the therapeutic effectiveness of MMT.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 620477     DOI: 10.1002/cpt1978232175

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Brain abscess complicating drug abuse.

Authors:  Takahito Hayashi; Claas Buschmann; Dejana Matejic; Benno Riesselmann; Michael Tsokos
Journal:  Forensic Sci Med Pathol       Date:  2012-06-15       Impact factor: 2.007

2.  Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.

Authors:  Andrew A Somogyi; Mie Larsen; Reza M Abadi; Jaroon Jittiwutikarn; Robert Ali; Jason M White
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state.

Authors:  E Anggård; M I Nilsson; J Holmstrand; L M Gunne
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

6.  Rapid determination of methadone in plasma, cerebrospinal fluid, and urine by gas chromatography and its application to routine drug monitoring.

Authors:  N Schmidt; R Sittl; K Brune; G Geisslinger
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

7.  Effect of urinary pH on the disposition of methadone in man.

Authors:  M I Nilsson; E Widerlöv; U Meresaar; E Anggård
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 8.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

9.  Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients.

Authors:  A J Hiltunen; P Lafolie; J Martel; E C Ottosson; L O Boreus; O Beck; S Borg; P Hjemdahl
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

10.  Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase.

Authors:  M I Nilsson; E Anggård; J Holmstrand; L M Gunne
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.